Abstract: Fixed-dried blood cells carrying an active agent are described, along with methods of making the same, methods of using the same, and compositions containing the same. The blood cells are preferably blood platelets.

Abstract: Fixed-dried blood cells carrying an active agent are described, along with methods of making the same, methods of using the same, and compositions containing the same. The blood cells are preferably blood platelets.

Abstract: Fixed-dried blood cells carrying an active agent are described, along with methods of making the same, methods of using the same, and compositions containing the same. The blood cells are preferably blood platelets.

Abstract: Fixed-dried blood cells carrying an active agent are described, along with methods of making the same, methods of using the same, and compositions containing the sane. The blood cells may be red blood cells or blood platelets.

Abstract: Fixed-dried red blood cells (RBCs), and processes for preparing the same are disclosed. The red blood cells, upon reconstitution with distilled water or appropriate buffer: bind oxygen with native affinities, have partial deformability, present minimal thrombogenicity to platelets, and have oblated blood group antigens. The RBCs are preferably fixed by means of cross-linkers with aldehyde functions such as paraformaldehyde or glutaraldehyde either alone or in combination. Native oxygen kinetics are achieved by preparing the red blood cells with 1,6-diphosphofructose. Blood group antigens and chemical functions that render the lyophilized RBCs thrombogenic are occluded by chemically attaching polyoxyethylene glycol polymers to the surface membrane of the red blood cells. The cross-linked red blood cells are preferably died by lyophilization.

Abstract: Fixed-dried blood cells carrying an active agent are described, along with methods of making the same, methods of using the same, and compositions containing the same. The blood cells may be red blood cells or blood platelets.

Abstract: Fixed-dried red blood cells (RBCs), and processes for preparing the same are disclosed. The red blood cells, upon reconstitution with distilled water or appropriate buffer: bind oxygen with native affinities, have partial deformability, present minimal thrombogenicity to platelets, and have oblated blood group antigens. The RBCs are preferably fixed by means of cross-linkers with aldehyde functions such as paraformaldehyde or glutaraldehyde either alone or in combination. Native oxygen kinetics are achieved by preparing the red blood cells with 1,6-diphosphofructose. Blood group antigens and chemical functions that render the lyophilized RBCs thrombogenic are occluded by chemically attaching polyoxyethylene glycol polymers to the surface membrane of the red blood cells. The cross-linked red blood cells are preferably died by lyophilization.

Abstract: Fixed-dried red blood cells (RBCs), and processes for preparing the same are disclosed. The red blood cells, upon reconstitution with distilled water or appropriate buffer: bind oxygen with native affinities, have partial deformability, present minimal thrombogenicity to platelets, and have oblated blood group antigens. The RBCs are preferably fixed by means of cross-linkers with aldehyde functions such as paraformaldehyde or glutaraldehyde either alone or in combination. Native oxygen kinetics are achieved by preparing the red blood cells with 1,6-diphosphofructose. Blood group antigens and chemical functions that render the lyophilized RBCs thrombogenic are occluded by chemically attaching polyoxyethylene glycol polymers to the surface membrane of the red blood cells. The cross-linked red blood cells are preferably died by lyophilization.

Abstract: Fixed-dried human blood platelets and processes for preparing the same are disclosed. The platelets, upon reconstitution: adhere to thrombogenic surfaces; do not adhere to non-thrombogenic surfaces; undergo shape change (spreading) upon adhering to a thrombogenic surface; adhere to one another to form a hemostatic plug upon adhering to a thrombogenic surface; and release their granular contents. Pharmaceutical formulations containing the same are also disclosed. The platelets are preferably fixed by means of a fixative such as formaldehyde, paraformaldehyde, or glutaraldehyde, or fixed by means of a permanganate fixate. The platelets are preferably dried by lyophilization.

Abstract: Fixed-dried human blood platelets and processes for preparing them are disclosed. The platelets, upon reconstitution: adhere to thrombogenic surfaces; do not adhere to non-thrombogenic surfaces; undergo shape change (spreading) upon adhering to a thrombogenic surface; adhere to one another to form a hemostatic plug upon adhering to a thrombogenic surface; and release their granular contents. Surgical aids containing such platelets are also disclosed. The platelets are preferably fixed by a fixative such as formaldehyde, paraformaldehyde, or glutaraldehyde, or fixed by a permanganate fixate. The platelets are preferably dried by lyophilization.

Abstract: A method for inactivating microbiological contaminants in a human blood platelet preparation is disclosed. The method comprises, first, providing blood platelets, particularly human blood platelets, suspected of being contaminated with microorganisms. The platelets are then contacted to a fixative for a time sufficient to fix the platelets. After fixing, the platelets are preferably washed and dried to produce fixed-dried platelets. The step of contacting the platelets to a fixative is carried out for a time sufficient to kill some or all the of the contaminating microorganisms.

Abstract: Fixed-dried human blood platelets and processes for preparing the same are disclosed. The platelets, upon reconstitution: adhere to thrombogenic surfaces; do not adhere to non-thrombogenic surfaces; undergo shape change (spreading) upon adhering to a thrombogenic surface; adhere to one another to form a hemostatic plug upon adhering to a thrombogenic surface; and release their granular contents. Pharmaceutical formulations containing the same are also disclosed. The platelets are preferably fixed by means of a fixative such as formaldehyde, paraformaldehyde, or glutaraldehyde, or fixed by means of a permanganate fixate. The platelets are preferably dried by lyophilization.

Abstract: Screening tests and bioassay of von Willebrand's factor (platelet aggregating factor) in human and animal blood plasma are effected using a reagent of blood platelets and snake venom having a positive platelet aggregating cofactor effect. The reagent and tests may also suitably employ dried blood platelets. The reagent may comprise dried platelets and either ristocetin or active snake venom as the platelet aggregating cofactor.

Abstract: Screening tests and bioassay of von Willebrand's factor (platelet aggregating factor) in human and animal blood plasma are effected using a reagent of blood platelets and snake venom having a positive platelet aggregating cofactor effect. The reagent and tests may also suitably employ dried blood platelets. The reagent may comprise dried platelets and either ristocetin or active snake venom as the platelet aggregating cofactor.